Kornimate/medical-research-clean huggingface dataset:
weight loss intervention for the reduction of cancer risk and health disparities in rural ohio

Conditions: Obesity-Related Malignant Neoplasm

Summary: this study determines the feasibility of a telephone-based weight lost intervention in reducing cancer risk and health disparities in rural ohio. obesity is the leading preventable cause of cancer, and obesity-related inflammation is linked to elevated cancer risk, independent of obesity itself. rural populations are a vulnerable population in need of increased access to tailored strategies and benefit from weight loss interventions. this study aims to see whether a telephone-based intervention may help obese people in rural area to reduce body weight, so as to prevent obesity-related cancer.

primary objectives: i. to determine the feasibility and acceptability of a 15-week telephone-based weight loss intervention among overweight/obese rural residents. ii. to estimate the preliminary efficacy of the lifestyle modifications on weight loss, body composition (fat mass, percent body fat), inflammatory biomarkers (il-6, tnf-alpha, and c-recreative protein \[crp\]), and other disease risk factors (lipid profiles). outline: participants are randomized to 1 of 2 arms. arm i: participants receive weekly telephone-based weight loss intervention for 15 weeks, including dietary recommendations tailored to their current weight and weight loss target, home-based aerobic and resistance exercise, and weekly telephone counseling session over 30-45 minutes. arm ii: participants receive education brochures describing the american institute for cancer research physical activity and dietary guidelines.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) \>= 25 kg/m\^2 * age: 20-64.9 years * not currently participating in any weight loss intervention or meet the physical activity recommendation (150 min/week of moderate-intensity exercise or 75 min/week of vigorous exercise) * the ability to walk two blocks * ability to speak and read english exclusion criteria: * prior cancer diagnosis (except non-melanoma skin cancer) or severe medical conditions such as unstable cardiovascular disease or digestive disorders that would preclude physical activity and dietary intervention * pregnant or nursing women * unable to give informed consent
surveillance of fungal infections during construction activity

Conditions: Aspergillosis

Summary: fungal infections in immunocompromised patients occuring during construction activities in hospitals have repeatedly been reported. however, the question of a causal relation between construction activities and infections has never been addressed systematically and prospectively. to answer this question, we will monitor our immunosuppressed patients' health status, as well as fine dust and aspergillus spore contents in the air during a three year construction activity period in our hospital.


Eligibility criteria:
inclusion criteria: * kidney transplantation * chronic hemodialysis treatment

Keywords: aspergillus infections immunosuppression kidney transplantation hemodialysis galactomannan test fine dust construction activity airborne aspergillus spores
the use of cannabidiol (cbd) in pain reduction and opioid use after shoulder arthroscopy

Conditions: Pain, Postoperative

Summary: this study is designed to evaluate the effects of administering cbd to control post-operative pain in patients undergoing shoulder arthroscopy. secondly, the purpose will be to evaluate the effectiveness of cbd in comparison with opioid therapy for post-operative pain.


Eligibility criteria:
inclusion criteria * patients undergoing an arthroscopic shoulder procedure (rotator cuff repair, decompression, labrum repair) * patients ages 18-75, inclusive * female patients must be currently practicing effective forms of two types of birth control, which are defined as those, alone or in combination, that result in a low failure rate (less than 1% per year) when used consistently and correctly * male patients must be using an effective form of contraception exclusion criteria * legally incompetent or mentally impaired (e.g., minors, alzheimer's subjects, dementia, etc.) * younger than 18 years of age * older than 75 years of age * any patient considered a vulnerable subject: pregnant women or fetuses, children, cognitively impaired adults, prisoners * history of cannabis abuse or dependence * history of coagulation abnormalities and thromboembolic disease or current abnormal coagulation test values * history of stroke or acute coronary syndromes within 3 months before surgery * abnormal coagulation profile * renal failure (serum creatinine \> 250 μmol/l \[2.83 mg/dl\]) or liver cirrhosis * patients with a history of hypersensitivity to percocet * patients that have been on pre-operative opioid management for any reason * patients meeting the dsm-v for major psychiatric illness, such as bipolar disorder * patients diagnosed with major depression, psychosis, or substance abuse disorder * patients with current or a history of suicidal ideation * breastfeeding females * patients with clinically significant illness, including cardiovascular disorders * clinically significant lab abnormalities * abnormal lfts * patients with major neurological disorders, such as dementia, parkinson's disease, cognitive impairment, epilepsy, history of traumatic brain/head injury, or seizures * patients with moderate (child-pugh b) and severe hepatic impairment (child-pugh c). * patients taking moderate or strong inhibitors of cyp3a4 and cyp2c19 (listed below) concomitantly * patients taking strong cyp3a4 and cyp2c19 inducers (listed below) concomitantly * patients taking substrates of utg1a9, utgb17, cyp2a1, cyp2b6, cyp2c8, cyp2c9 and cyp2c19 (listed below) concomitantly
epidemiology and genomic surveillance of staphylococcus aureus in icu neonatology

Conditions: the Aim of This Study is to Describe Genomic Epidemiology of MSSA in Neonatal ICU

Summary: newborns hospitalized in neonatology are particularly vulnerable to infections, in particular healthcare associated infection (hai). staphylococcus aureus represents the 2nd microorganism responsible for sepsis, this infection is particularly serious and like any hai, it increases the length of hospitalization of newborns and neonatal morbidity. in september 2020, the cdc published recommendations for the prevention and control of staphylococcus aureus infections in neonatal intensive care unit/icu. they specify the indications for implementing a mssa surveillance strategy as well as the screening and management methods. despite the absence of a defined strategy at the national level, our establishment chose to initiate management measures several years ago following serious infections and mssa epidemics in neonatal intensive care unit/icu. with the aim of improving the efficiency of care and evaluating the strategy chosen at the establishment, it is necessary to describing * the epidemiology of mssa carriage and infections * cross-transmission of mssa strains between patients * the success rate of decolonization * the sensitivity of detection of digestive carriage by stool swabbing in order to limit the number of samples from newborns.


Eligibility criteria:
inclusion criteria: * newborns hospitalized in neonatal icu * mssa carrier exclusion criteria: * none

Keywords: cross-transmission prevention and infection control bacterial typing
evaluation of chemotherapy influence on clinical and biological markers of ovarian reserve

Conditions: Infertility

Summary: the objective is to evaluate the influence of chemotherapy, either for auto-immune disease, either for carcinologic disease, on clinical and biological markers of ovarian reserve, for young patients, with normal reproductive functions.

the study will enrol patients between 18 and 35 years, treated with neoadjuvant or adjuvant chemotherapy for systemic lupus erythematosus (group 1), breast cancer (group 2) or hodgkin disease (group 3)to evaluate the clinical and biological markers of ovarian reserve. the follow-up will last 24 months for each patients with a visit before treatment, and at 3 months, 6 months, one year and two years after treatment. during this period, we will collect pre and post treatment clinical data,and biological data and ultrasonographic data such as antral follicle count which is a marker of ovarian follicle reserve.these data were not observed in current practice.

Eligibility criteria:
inclusion criteria: * women volunteers treated by chemotherapy, * ≥ 18 and ≤ 35 years old * regular menstrual cyclicity, between 25 and 35 days * social security affiliation * signed informed consent exclusion criteria: * women \ 35 years old * pregnancy * emergent treatment necessity * no social security affiliation * virgin patients

Keywords: fertility chemotherapy
dose finding study to assess octenidine mouthwash concentrations in comparison to placebo

Conditions: Gingivitis

Summary: the objective of this clinical trial is to identify the most efficacious octenidine dihydrochloride concentration regarding bacterial count reduction in comparison to a placebo in the oral cavity.


Eligibility criteria:
inclusion criteria: * patients with mild gingivitis (mean gi: 0.2 - 1.0) * patients with complete natural "ramfjord-teeth" or their replacement teeth * caucasian * signed informed consent exclusion criteria: * patients with severe systemic diseases (diabetes, hepatitis, hiv, tuberculosis, cancer) * patients who require endocarditis prophylaxis for dental examination and treatment * caries requiring treatment (e.g. caries with cavity) or other oral diseases (incl. gingival hyperplasia, diseases of the oral mucosa, periodontal screening index psi \> 2) * patients with orthodontic appliances and removable dentures * patients treated with antibiotics less than 3 months prior to the baseline examination at v1 and/or such a treatment planned for the duration of the trial * patients chronically treated with steroids * patients who suffer from xerostomia * patients who regularly smoke more than 10 cigarettes per day * patients who have a known hypersensitivity or allergy to the test product and its ingredients or to medications that have a similar chemical structure * participation of the patient in another clinical trial within the last four weeks before enrollment in this trial * incapability of assessing essence and possible consequences of the trial (e.g. alcoholism) * pregnant or breastfeeding women * women with childbearing potential except those who fulfill the following criteria: * post-menopausal (12 month of natural amenorrhoea or 6 months of amenorrhoea with serum fsh \> 40 u/ml) * postoperative (6 weeks after bilateral ovariectomy with or without hysterectomy) * continuous and correct application of a contraception method with a pearl index \< 1% (e.g. implants, depots, oral contraceptives, intrauterine device - iud)
evaluation of salt sensitivity in young adults

Conditions: Healthy Volunteers

Summary: the current prospective cross-sectional pilot study is proposed to determine a set of characteristic factors associated with salt sensitivity in young adults by measuring blood pressure, serum aldosterone levels, urine analysis, arterial pulse wave velocity and central arterial pressure in response to short term increases in salt intake.

since salt sensitivity at an early age is associated with subsequent hypertension and an increase in mortality, intervention by lifestyle modification including the reduction of sodium intake could prevent subsequent increases in blood pressure and development of hypertension, cardiovascular disease and death. it would therefore be beneficial to have a simple method of identifying salt sensitive young adults so that risk factor modification can be achieved to prevent progression of the effects of hypertension on heart function. this study is a longitudinal pilot study to identify characteristics of salt sensitive young adults so that this population of people can be identified early on and appropriate lifestyle modifications can be made to prevent the subsequent progression of hypertension and cardiovascular disease. the study will be conducted at 2 visits separated by one week. at the first visit, eligible subjects will be asked to complete questionnaires regarding childhood and current sodium intake.subjects will be asked about family history of hypertension and cardiovascular disease. subjects will also undergo blood pressure measurement in both arm, and will provide a blood sample and spot urine sample. subjects will then be asked to take salt pills 3 times a day for one week, and then return to the study center for a repeat of the above measurements.

Eligibility criteria:
inclusion criteria: * young adults age 21-30 * able and willing to provide written informed consent exclusion criteria: * any cardiovascular or other chronic health problem * chronic medications besides oral contraceptive pills in women * bmi\>30kg/m2 * blood pressure \>140/90 mmhg * inability or unwillingness to adhere to study procedures
quilt-2.019: a study of amg 655 or amg 479 in combination with gemcitabine for treatment of metastatic pancreatic cancer

Conditions: Adenocarcinoma of the Pancreas; Metastatic Pancreatic Cancer; Pancreatic Cancer

Summary: this is a multi-center, 2-part study of amg 655, amg 479 or amg 655-placebo plus gemcitabine as first-line treatment of subjects with metastatic pancreatic cancer. part 1 is an open-label, dose-escalation phase 1b segment to determine the safety, tolerability and maximum tolerated dose of amg 655 in combination with gemcitabine. enrollment into part 1 of the study has been completed. part 2 is a randomized, placebo-controlled phase 2 segment to estimate the efficacy as assessed by 6 month survival of amg 655, amg 479, or amg 655-placebo in combination with gemcitabine. the phase 2 segment that will commence after dose selection in part 1. in part 2, subjects will be randomized 1:1:1 to amg 655, amg 479, or placebo in combination with gemcitabine.


Eligibility criteria:
inclusion criteria: * untreated metastatic adenocarcinoma of the pancreas (ajcc stage iv) * subjects with unresectable pancreatic cancer who have had surgery are eligible if fully recovered and greater than 30 days have elapsed since the surgery. subjects with a history of pancreatoduodenectomy are eligible provided that there is radiographically documented disease recurrence. * men or women ≥ 18 years of age * eastern cooperative oncology group (ecog) score of 0 or 1 * adequate hematologic, hepatic, renal and coagulation function * amylase and lipase ≤ 2.0 x uln * adequately controlled type 1 or 2 diabetic subjects exclusion criteria: * islet cell, acinar cell carcinoma, non-adenocarcinoma (eg, lymphoma, sarcoma, etc), adenocarcinoma originated from biliary tree or cystadenocarcinoma * known central nervous system metastases * uncontrolled cardiac disease or any other co-morbid disease that would increase the risk of toxicity * adjuvant chemotherapy or chemoradiotherapy

Keywords: amg 479 gemcitabine tr-2 igf-1r amg 655 pancreatic cancer adenocarcinoma of the pancreas metastatic pancreatic cancer
2d-radiotherapy in palliation of advanced esophageal cancer

Conditions: Palliative Care

Summary: the study wants to define the efficacy of a short course 2d-radiation therapy in patients with symptomatic advanced esophageal cancer.

the study wants to define the efficacy of a short course accelerated 2d-radiation therapy delivered in twice daily fractions and 2 consecutive days for symptomatic palliation of advanced esophageal cancer.

Eligibility criteria:
inclusion criteria: * histologically proven advanced esophageal cancer * excluded from curative therapy because of disease stage and/or presence of multiple comorbidities and/or poor performance status * age \> 18 years * eastern cooperative oncology group (ecog) \<3 exclusion criteria: * prior radiotherapy to the same region

Keywords: palliative care radiotherapy pain quality of life esophageal cancer
the anxiety of parents of children undergoing cardiac surgery

Conditions: Anxiety

Summary: this is a randomized clinical trial. the population consisted of parents of children undergoing cardiac surgery from december 2010 to april 2011. we included parents aged over 18 years, and the following were considered exclusion criteria: inability to understand and/or answer the questions for any reason, parents of children undergoing surgery for insertion of the pacemaker and defibrillator, surgical death and not take up the case. 22 parents in the intervention group were randomized and received standardized guidelines for nursing and 22 parents participated in the control group received the guidelines and routine of the institution. anxiety was assessed using the stai state-trait inventory in the preoperative period and 48 hours after surgery the child.

anxiety

Eligibility criteria:
inclusion criteria: * we included parents aged over 18 years exclusion criteria: * inability to understand and/or answer the questions for any reason, * parents of children undergoing surgery for insertion of the pacemaker and defibrillator, * surgical death and not take up the case

Keywords: guidelines for nursing anxiety cardiac surgery pediatrics
copd co-infection with tuberculosis on th17 cell differentiation

Conditions: Tuberculosis Infection; Chronic Obstructive Pulmonary Disease

Summary: this project will observe and follow up the changes of pulmonary function and ct in patients with smoking combined with pulmonary tuberculosis, and measure the ratio of th1 cells, th17 cells, macrophages and neutrophils and the secretion of factors such as tnf-α, ifn-γ and il-17 in pulmonary blood and alveolar lavage fluid.

chronic obstructive pulmonary disease (copd) and tuberculosis are major global health problems, and acquired and acquired immunity play an important role in copd and tuberculosis, and there is an interaction between copd and tuberculosis, but the exact mechanism is not clear. pre-existing tb infection is an independent risk factor for copd and can aggravate pulmonary function and increase hospitalization and mortality in copd patients. in copd patients, th1 and th17 cells are involved in the development of copd and emphysema through activation of macrophages and recruitment of neutrophils, while matrix metalloproteinases (mmps) of macrophage and neutrophil origin are involved in the formation of tuberculosis cavities, and cytokines such as tnf-α, ifn-γ, il-17 are involved in the mechanism of their destruction, il-17 restricts the expression of hif-1α to inhibit the development of tb granulomas, and ct analysis revealed that combined tb exacerbates emphysema in copd patients. the above evidence suggests that tuberculosis plays an important role in the formation of emphysema in copd. in this project, we will observe and follow up the changes of pulmonary function and ct in patients with smoking combined with pulmonary tuberculosis, and examine the ratio of th1 cells, th17 cells, macrophages and neutrophils and the secretion of tnf-α, ifn-γ, and il-17 in pulmonary blood and alveolar lavage fluid.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of copd * age ≧ 40 exclusion criteria: * presence of other chronic respiratory diseases other than copd, such as asthma, bronchiectasis, interstitial lung disease, etc. * history of chest and lung surgery. * history of malignancy. * autoimmune disease. * long-term oral glucocorticoids, immunosuppressants and inhaled glucocorticoids. * mental abnormalities, cognitive impairment, inability to cooperate with pulmonary function and other tests. * acute stage of infection, such as lung infection, urinary tract infection and gastrointestinal tract infection, etc.
prediction of dysplasia within sessile serrated polyps using endoscopic imaging; a prospective observational study

Conditions: Sessile Serrated Adenoma

Summary: study of endoscopic imaging in the detection of dysplasia within serrated colonic lesions \>= 8mm in size

observational study structured endoscopic imaging protocol devised applied prospectively to sequential ssp \>= 8mm detected in a tertiary endoscopic resection cohort review of specimens by blinded specialist pathologists review of incongruent cases by endoscopists and pathologists

Eligibility criteria:
inclusion criteria: * patients referred to a tertiary endoscopic resection practice with any sessile serrated polyp (ssp) \>= 8mm exclusion criteria: * patients referred to a tertiary endoscopic resection practice without sessile serrated polyps (ssp)

Keywords: colonoscopy endoscopic resection sessile serrated adenoma
efficacy and safety of activated recombinant human factor vii in refractory haemorrhagic cystitis

Conditions: Other Haemostasis Disorder; Haemorrhagic Cystitis

Summary: this trial is conducted in the united states of america (usa). the aim of this trial is to assess the efficacy of activated recombinant human factor vii in the treatment of refractory haemorrhagic cystitis (hc) following chemotherapy.


Eligibility criteria:
inclusion criteria: * severe haemorrhagic cystitis (hc) exclusion criteria: * patients with overt dic (disseminated intravascular coagulation) * patients with known active atherosclerotic disease, such as active coronary artery disease or recent stroke in the past 3 months * central venous access device related thrombus in the last 3 months * patients with allergy to activated recombinant human factor vii or any component of its preparation
clinical study to evaluate the rxsight light adjustable lens with the light delivery device in subjects with preoperative corneal astigmatism

Conditions: Cataract

Summary: for patients undergoing cataract surgery, the purpose of this study is to evaluate a patient's far vision without glasses and quality of vision after implantation and uv treatment of the rxsight light adjustable lens (rxlal).following completion of all light treatments, the patient's far vision without glasses and quality of vision will be assessed 6 months postoperatively.


Eligibility criteria:
inclusion criteria: * must sign a written informed consent form and be willing to undergo cataract surgery for the bilateral implantation of the rxlal. * greater than the age of 40 on the day the cataract surgery is performed. * preoperative keratometric cylinder of \>=0.50 d and \<=4.00 d in both eyes. * cataract causing reduction in best corrected distance visual acuity (bcdva) to a level of 20/32 or worse with or without glare source in both eyes. * willing and able to comply with the requirements for study specific procedures and visits. exclusion criteria: * zonular laxity or dehiscence. * age-related macular degeneration involving the presence of geographic atrophy or soft drusen. * retinal degenerative disorder or macular disorder (other than mild macular degeneration) that is expected to cause future vision loss. * history of uveitis * keratoconus or suspected of having keratoconus. * previous corneal or intraocular surgery, except eyes with previous pterygium excision are permitted as long as the pterygium did not extend more than 2mm onto the cornea from the limbus. * serious co-morbid conditions that in the judgement of the investigator makes inclusion in the study not in the best interest of the subject. * subjects taking systemic medications that may increase sensitivity to uv light. * subjects taking a systemic medication that is considered toxic to the retina such as tamoxifen. * history of ocular herpes simplex virus * history of congenital color vision defect

Keywords: cataract surgery eye disease lenticular opacification